Sun Life Financial Inc.

Sun Life reported underlying net income of CAD 1.12 billion, up from CAD 1.02 billion a year ago, and underlying EPS of CAD 2.02, up 13% year-over-year. Underlying return on equity was 19.1%; reported net income was CAD 1.01 billion versus CAD 716 million last year. By segment, Sun Life Asset Management underlying net income was CAD 262 million, up 4%; Canada underlying net income was CAD 427 million, up 23%; U.S. underlying net income increased 15%; and Asia underlying net income increased 21%. On the balance sheet, LICAT was 145%, holding company cash was CAD 2.3 billion, book value per share grew 3% to CAD 42.49, and financial leverage was 23.8%. Management did not give explicit full-year financial guidance, but reiterated medium-term objectives of 10% underlying EPS growth, about 20% underlying ROE, a 40%-50% dividend ratio, and organic capital generation in a 30%-40% range. It also said U.S. dental earnings should improve gradually over time, while the state/Medicaid dental business remains a longer-term turnaround and 2027 is a key market dynamic to watch.

Kevin Strain said the quarter was evidence that Sun Life is becoming a more diversified, global, growth-oriented company. He emphasized broad-based strength in Canada, Asia, U.S. health and risk solutions, and accelerating asset management momentum, while highlighting the company’s disciplined execution and strong capital position. His tone was confident but measured, with repeated remarks that the company is on track against medium-term objectives rather than making short-term promises.

Tim Deacon focused on the drivers behind the quarter’s numbers: underlying net income of CAD 1.12 billion, underlying EPS of CAD 2.02, and reported net income of CAD 1.01 billion. He attributed the gap between underlying and reported results mainly to acquisition and integration costs in SLC in the U.S., intangible amortization, and modestly unfavorable market impacts. He also pointed to CAD 4.7 billion of capital raising and CAD 6.2 billion of deployment activity in asset management, a CAD 750 million sub-debt issuance at a very favorable spread, organic capital generation of 41%, and returning CAD 0.5 billion to shareholders through dividends plus 0.8 million shares repurchased under the NCIB.

Analysts pressed management on the U.S. stop loss result, asking why strong sales and stable margins were not translating into even more earnings growth. Management said Q2 included expected seasonal IBNR reserve build, that loss ratios stayed in the mid-70s target range, and that broader health and benefits results were held back by a softer employee benefits business versus a record prior-year quarter. Questions also focused on U.S. dental and Medicaid: management said the state business will remain a drag for years, membership is expected to stay lower this year, and the mix shift toward commercial dental will take one to two years. In Asia, analysts asked about Hong Kong MCV exposure; management said MCV is about 30% of Hong Kong sales, about 10% of the high-net-worth business, and does not change the underlying momentum, though competitive pricing and market dynamics are affecting CSM margins.